Abstract: Objective: To compare the efficacy and safety of secukinumab and adalimumab in the treatment of nail psoriasis. Methods: The patients with nail psoriasis and treated with secukinumab or adalimumab at the Department of Dermatology and Venereology of Tianjin Medical University General Hospital from January 2020 to March 2023 were retrospectively analyzed. The efficacy and safety of the two groups were evaluated after 0, 4, 12, 24 and 36 weeks of administration, respectively. The t test was used to compare the measurement data between the two groups, and the Fisher exact test was used to compare the count data between the two groups, to analyze the improvement of NAPSI before and after treatment in the two groups. Results: A total of 36 patients were collected, including 17 treated with secukinumab and 19 treated with adalimumab. The NAPSI score decreased by 7.60±4.34, 13.20±4.09, 17.60±3.79 and 21.20±4.87, and the decreasing rates of NAPSI score were (13.87±8.80)%, (24.13±9.44)%, (32.11±8.87)% and (38.41±9.64)% after 4, 12, 24 and 36 weeks in secukinumab treatment group. The NAPSI score decreased by 12.17±5.49, 25.67±9.69, 38.67±15.54, 34.67±18.49 and the decreasing rates of NAPSI score were (20.19±7.20)%, (45.34±11.96)%, (62.64±18.59)% and (71.83±19.64)% after 4, 12, 24 and 36 weeks in adalimumab treatment group. Conclusions: Secukinumab and adalimumab were equally effective in the treatment of nail psoriasis at week 4. At the 12th week of treatment, the efficacy of adalimumab began to be better than that of secukinumab. At the 24th week of treatment, adalimumab was significantly more advantageous.

Key words: nail psoriasis, biological agents, adalimumab, secukinumab, efficacy evaluation